GATA1-mutation associated leukemia in children with trisomy 21 mosaic;GATA1-Mutations-assoziierte Leukämien bei Kindern mit Trisomie 21-Mosaik

Klinische Padiatrie

Volumn 224, Issue 3, 2012, Pages 153-155

  Reinhardt, D ^a   Reinhardt, K ^a   Neuhoff, C ^a   Sander, A ^a   Klusmann, J H ^a   Pekrun, A ^b   Sauerbrey, A ^c   Von Stackelberg, A ^d   Rossig C ^e   Creutzig, U ^a   Kolenova, A ^f  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Klinikum Bremen   (Germany)

^c HELIOS KLINIKUM ERFURT   (Germany)

^d Pädiatrische Hämatologie und Onkologie ^*  (Germany)

^e UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^f Bratislava   (Slovakia)

Author keywords

AML; mosaic; transient leukemia; trisomy 21

Indexed keywords

CYTARABINE; TRANSCRIPTION FACTOR GATA 1;

ACUTE MEGAKARYOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER REGRESSION; CAUSE OF DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DOWN SYNDROME; FOLLOW UP; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; HEART DISEASE; HIGH RISK PATIENT; HUMAN; IMMUNOPHENOTYPING; INFANT; LOW DRUG DOSE; NEWBORN; RETROSPECTIVE STUDY;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CYTARABINE; DOWN SYNDROME; FEMALE; FOLLOW-UP STUDIES; GATA1 TRANSCRIPTION FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA, MEGAKARYOBLASTIC, ACUTE; LEUKEMIA, MYELOID, ACUTE; MALE; MOSAICISM; MUTATION; MYELOPOIESIS; MYELOPROLIFERATIVE DISORDERS;

EID: 84860577647     PISSN: 03008630     EISSN: 14393824     Source Type: Journal    
DOI: 10.1055/s-0032-1308988     Document Type: Article

References (18)

1. Alford K A, Reinhardt K, Garnett C et al. Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia. Blood: 2011; 118 2222 2238
2. Creutzig U, Ritter J, Ludwig W-D et al. Akute myeloische Leukämie bei Kindern mit Down-Syndrom. Klin Pädiatr: 1995; 207 136 144
3. Creutzig U, Ritter J, Vormoor J et al. Transiente Myeloproliferation und akute myeloische Leukämie bei Säuglingen mit Morbus Down. Klin Pädiatr: 1990; 202 253 257 (Pubitemid 20219657)
4. Creutzig U, Zimmermann M, Lehrnbecher T et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol: 2006; 24 4499 4506 (Pubitemid 46646248)
5. Doyle J J, Thorner P, Poon A et al. Transient leukemia followed by megakaryoblastic leukemia in a child with mosaic Down syndrome. Leuk Lymphoma: 1995; 17 345 350
6. Hasle H. Pattern of malignant disorders in individuals with Down's syndrome. Lancet Oncol: 2001; 2 429 436 (Pubitemid 33585947)
7. Homans A C, Verissimo A M, Vlacha V. Transient abnormal myelopoiesis of infancy associated with trisomy 21. Am J Pediatr Hematol Oncol: 1993; 15 392 399 (Pubitemid 23320137)
8. Isaacs H Jr. Fetal and neonatal leukemia. J Pediatr Hematol Oncol: 2003; 25 348 361 (Pubitemid 36569965)
9. Klusmann J H, Creutzig U, Zimmermann M et al. Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. Blood: 2008; 111 2991 2998
10. Klusmann J H, Godinho F J, Heitmann K et al. Developmental stage-specific interplay of GATA1 and IGF signaling in fetal megakaryopoiesis and leukemogenesis. Genes Dev: 2010; 24 1659 1672
11. Klusmann J H, Li Z, Bohmer K et al. miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia. Genes Dev: 2010; 24 478 490
12. Kudo K, Hama A, Kojima S et al. Mosaic Down syndrome-associated acute myeloid leukemia does not require high-dose cytarabine treatment for induction and consolidation therapy. Int J Hematol: 2010; 91 630 635
13. Langebrake C, Creutzig U, Dworzak M et al. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group. J Clin Oncol: 2006; 24 3686 3692 (Pubitemid 46630545)
14. Langebrake C, Creutzig U, Reinhardt D. Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts. Klin Padiatr: 2005; 217 126 134 (Pubitemid 40705232)
15. Massey G V, Zipursky A, Chang M N et al. A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481. Blood: 2006; 107 4606 4613 (Pubitemid 43882604)
16. Sandoval C, Pine S R, Guo Q et al. Tetrasomy 21 transient leukemia with a GATA1 mutation in a phenotypically normal trisomy 21 mosaic infant: case report and review of the literature. Pediatr Blood Cancer: 2005; 44 85 91 (Pubitemid 39602572)
17. Stepensky P, Brooks R, Waldman E et al. A rare case of GATA1 negative chemoresistant acute megakaryocytic leukemia in an 8-month-old infant with trisomy 21. Pediatr Blood Cancer: 2010; 54 1048 1049
18. Yanase K, Kato K, Katayama N et al. Transient abnormal myelopoiesis in a cytogenetically normal neonate. Int J Hematol: 2010; 92 527 530